Targeting Premature Ageing Conditions
A single company with two pathways for healthy aging and to fight senescence
Senolytic Drug discovery
Senolytic drug candidates developed as 'pan-senolytics,' designed to target a broad and diverse range of senescent cells accumulating throughout the body due to premature ageing. These candidates are being engineered with a strong focus on achieving both high efficacy and an excellent safety profile, aiming to advance preclinical development and lay the groundwork for innovative treatments in areas of significant medical need.
Medical Food
FlavoLife has developed the first platform of innovative senolytic medical foods for cancer. Most chemotherapies used for major cancer types induce cellular senescence. These senescent cells persist in tissues, causing local and systemic inflammation, which worsens chemotherapy's side effects. As a result, targeting senescent cells has become a strategy for reducing chemotherapy toxicity.
Pioneering Innovation
Redefining Ageing
Empowering Health
Supported by
